Michael R. Hayden, Director at AbCellera Biologics Inc. (ABCL), bought 30,000 shares at $5.90 ($177K) on 2023-08-08, disclosed to the SEC on 2023-08-09.
Open-market purchase of $177k ABCL by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Nothing distinguishes this filing.
| Filing → |
| IONS | BUY | 2026-07-31 | $1.1M | — | Filing → |
| IONS | BUY | 2025-05-02 | $478K | — | Filing → |
| IONS | BUY | 2024-12-26 | $272K | — | Filing → |